‘I Am A Woman’: Track Star Caster Semenya Continues Her Fight to Compete As A Female
Caster Semenya of South Africa races to the line to win the Women’s 800 meters during the IAAF Diamond League event at the Khalifa International Stadium on May 03, 2019 in Doha, Qatar. Semenya has appealed a ruling that requires her to reduce her testosterone levels by drugs or surgery.
Francois Nel/Getty Images
hide caption
toggle caption
Francois Nel/Getty Images
This week, the Olympic champion runner Caster Semenya of South Africa filed an appeal in a case that hinges on her right to compete as a woman. It’s the latest chapter in a fight that’s gone on for years, and that raises thorny questions about fairness and ethics in sport.
Semenya, 28, is a two-time gold medalist in the 800 meter event. She is asking the Swiss Federal Supreme Court to throw out a ruling issued earlier this month by the Court of Arbitration for Sport, or CAS, which is based in Lausanne.
That ruling upheld regulations that will require some female track athletes with naturally-elevated testosterone levels to lower those levels with drugs or surgery, if they want to compete in certain women’s events on the international stage.
Just two days after losing that court fight, Semenya took to the track in the Diamond League championships in Doha, Qatar, and blistered past the competition in her marquee event, the 800 meters.
Caster Semanya competes in the Diamond League championships in Doha, Qatar.
YouTube
“My word! Is there any end to her talent?” marveled an announcer as he watched Semenya pull away from the pack in the home stretch. “Is this, as some people have suggested, something of an act of defiance, given what’s been going on?”
In a statement when she filed her appeal, Semenya said, “I am a woman and I am a world-class athlete. The IAAF will not drug me or stop me from being who I am.”
The IAAF is the International Association of Athletics Federations, the international governing body for track and field, which imposed the regulations, arguing that the rules are necessary to create a level playing field in women’s events.
In its 2-1 ruling, CAS found that while the regulations are discriminatory, “such discrimination is a necessary, reasonable and proportionate means of achieving the legitimate objective of ensuring fair competition in female athletics.”
It’s not simple to define sex
The IAAF regulations apply to certain athletes with what are known as Differences of Sex Development, or DSDs, which means they were born with anatomy that doesn’t neatly fit into the binary, male or female categories. These individuals are also known as intersex.
“People think that it’s simple to define sex. It’s not,” says Dr. Eric Vilain, a geneticist who specializes in the study of sexual development at Children’s National Health System and George Washington University in Washington, D.C.
Dr. Vilain, who testified as an expert witness on Caster Semenya’s behalf, explains that the biology of sex classification is anything but straightforward; there can be a wide spectrum of variations.
“It’s really difficult to support a rule that seems to be based more on a preconceived idea of what a woman should be, rather than who a woman is,” he says.
Caster Semenya was raised as a female and is legally female. She’s fighting rules that affect DSD athletes who have what are typically male, XY chromosomes; who were born with internal testes; and have testosterone levels higher than the typical female range.
An unfair advantage?
Supporters of the rules say higher testosterone gives these athletes an unfair performance advantage, since it provides a boost in power, endurance, and speed.
So, they say, if you want to create a level playing field, the new restrictions make sense.
“Fairness is an extremely subjective word,” says Joanna Harper, who researches gender and sport, and testified on behalf of the IAAF. “I prefer the word equitable.”
Harper says, “We separate male athletes and female athletes not on the basis of gender identity, or legal sex, or how people are identified at birth, but rather on biological characteristics that make men so much better at sport than women.”
Harper, author of a forthcoming book entitled Sporting Gender: the History, Science and Stories of Transgender and Intersex Athletes, argues that the rules should not be seen as stripping a female athlete of her identity.
“Whether someone is a woman or someone is a man or perhaps somewhere in between, is a very complicated thing,” Harper says. “The separation of athletes into male and female categories is something that I call creating an ‘athletic gender.’ And it’s merely one component of a human being’s existence.”
Creating a ‘protected space’ for women to compete
For Duke Law School professor Doriane Coleman, the IAAF rules guarantee a “protected space” for women to compete. Coleman is a former 800 meter runner who studies sex and sport.
“If eligibility for women’s sports events can’t be based on biological sex traits, or at least one biological sex trait,” she says, “then you won’t see females on the podium.”
Silver medalist Francine Niyonsaba (L) of Burundi, gold medalist Caster Semenya (R) of South Africa and bronze medalist Margaret Nyairera Wambui (C) of Kenya stand on the podium during the medal ceremony for the Women’s 800 meter at the Rio 2016 Olympic Games.
Patrick Smith/Getty Images
hide caption
toggle caption
Patrick Smith/Getty Images
Coleman points to the women’s 800 meter final at the 2016 Olympic games in Rio de Janeiro, where all three podium spots were won by women who say they will be affected by the new rules on DSD athletes: Caster Semenya, who took gold; Francine Niyonsaba of Burundi, who won silver; and Margaret Wambui of Kenya, who won bronze.
“It was very frustrating to watch it happen,” Coleman says. “It wasn’t about the individuals; it was about the goals of women’s sport … And it was really hard to know that on that day there would not be a female, biologically speaking on the podium in the women’s 800.”
Definitions are difficult
But how to define exactly who is a biological woman is not at all clear-cut.
“Sex is not defined by one particular parameter,” says geneticist Eric Vilain. What’s more, he says, “for many human reasons, it’s so difficult to exclude women who’ve always lived their entire lives as women — to suddenly tell them ‘you just don’t belong here.’ Because the implication is to tell them ‘well, you’re not really a woman.’ And I think society should not accept that easily.”
The new rules apply only to certain distance events, from 400 meters to one mile, where, the IAAF claims, runners get the most performance benefit from testosterone. Scientists who testified on behalf of Semenya dispute those data.
If the affected athletes want to race in those restricted events, the IAAF says, they can compete in the male classification.
Dr. Vilain says that’s absurd: “If the same athlete could be a woman in one and a man in another, it makes absolutely no sense,” he says.
Medically suppressing testosterone
As for how the DSD athletes can suppress their testosterone, they have three choices: they can have their testes surgically removed; they can get a monthly injection that blocks testosterone; or they can take birth control pills.
But all of those options — even birth control pills — come with risks, says Dr. Veronica Gomez-Lobo, the founder of the Differences of Sex Development clinic at Children’s National Health System.
“Even though we tend to think of [oral contraceptives] as being very safe,” she says, “they can cause blood clots that can travel to your lung and and can be very dangerous. And although that’s very rare, that can happen. So you’re forcing somebody to take a medication she doesn’t need and she doesn’t want to take, and she’s incurring the side effects and risks of that medication only to compete.”
‘Inverse doping’
The World Medical Association, or WMA, is so angered by the IAAF regulations that they’ve urged doctors around the world to refuse to comply. The WMA calls the regulations unethical and a violation of human rights.
“There is no medical need and no medical indication for this therapy, and therefore, doctors should not prescribe it,” says Dr. Frank Montgomery, the WMA’s chair of council.
Montgomery calls it “inverse doping” to require athletes to take drugs that will sabotage their performance.
“We are against doping of any sort,” Montgomery says. “Ethically and medically this fairness argument doesn’t carry. It is definitely not a way to tell someone you’re a woman only if you take certain medications.”
None of this is simple.
“No matter what you do, you’re going to end up hurting someone. And I think that’s what makes this topic so difficult,” says Steve Magness, who coaches professional runners and writes about the science of performance.
“You can at the same time feel incredible compassion toward Semenya and DSD athletes and say that ‘hey, what’s happening isn’t right’. But at the same time, you can say we protect the women’s division of sport for a reason and we have to decide somewhere where we want to divide that.”
For now, these rules apply only to track and field. It will be up to other sports federations to decide whether to follow suit.
Catch The Wave: Commonalities Of Surfing And Finances
In recent years, technology, education and government regulation have helped make the sport of surfing and finance less risky. Both have a lot in common and teach us a lot about risk.
Louisiana Governor Says He Plans To Sign Bill Restricting Most Abortions Into Law
Louisiana is the latest state where lawmakers have voted to ban most abortions with no exceptions for cases of rape or incest. The state’s Democratic governor says he will sign the bill into law.
The Regulations Allegedly Violated By The Last Clinic Offering Abortions In Missouri
NPR’s Audie Cornish speaks with Dr. Randall Williams, director of the Missouri Department of Health and Senior Services, about the investigation he is overseeing into Missouri’s only abortion clinic.
NBA Finals Head To Canada As Raptors Take On Golden State Warriors
For the first time, the NBA Finals will be played in Canada. The Toronto Raptors host the Golden State Warriors on Thursday. NPR’s Audie Cornish talks with Toronto Star sports columnist Bruce Arthur.
The Thistle & Shamrock: Scent Of Spring
Kim Robertson
/Courtesy of the artist
hide caption
toggle caption
/Courtesy of the artist
Spring is in the airs… and in the jigs, reels, and songs as we put out a musical welcome mat for the first signs of the season. Artists featured in this episode include Nightnoise, Kim Robertson and The Whistlebinkies.
Old Fight, New Front: AIDS Activists Want Lower Drug Prices. Now!
During testimony before a congressional hearing on drug prices this month, Dr. Aaron Lord (left), a patient advocate and AIDS activist, publicly challenged Daniel O’Day, CEO of Gilead Sciences (right), to lower the price of Gilead’s HIV prevention drug Truvada.
Bill O’Leary/The Washington Post/Getty Images
hide caption
toggle caption
Bill O’Leary/The Washington Post/Getty Images
When the first HIV drug, AZT, came to market in 1987, it cost $10,000 a year.
That price makes Peter Staley laugh today. “It sounds quaint and cheap now, but $10,000 a year at that time was the highest price ever set for any drug in history,” he says.
At the time, the price Burroughs Wellcome set for the drug sparked outrage. The AIDS epidemic was an urgent national crisis. For many, the diagnosis was a death sentence. The TV-viewing public was horrified by endless images of young men, suddenly sick and dying. A lost generation.
ACT UP — the AIDS Coalition to Unleash Power — was established by Staley and others to drive government attention and research toward a cure. A key early goal of the movement: force down the price of AZT. Whatever it took.

Demonstrators from the organization ACT UP, angry with the federal government’s response to the AIDS crisis, protest in front of the headquarters of the Food and Drug Administration in Rockville, Md., on Oct. 11, 1988, and effectively shut it down. By mid-morning some 50 of the protesters were arrested.
J. Scott Applewhite/AP
hide caption
toggle caption
J. Scott Applewhite/AP
“I led an action where we invaded [Burroughs Wellcome] headquarters in April of 1989 and sealed ourselves into a third floor office and caused $9,000 of property damage,” Staley says. “In September, we infiltrated the New York Stock Exchange before the opening bell with fake IDs and got into a VIP balcony and unfurled a banner that said ‘Sell Wellcome,’ and set off Marine fog horns that drowned out the opening bell. And we threw out fake $100 bills to the traders below us.”
He can’t quite remember, but thinks the fake bills read, “F*** your profiteering, we die while you play business.”
“The company lowered the price another 20% three days after that,” Staley says.
Because of ACT UP’s effectiveness, he says, the price of AZT went from $10,000 a year to $3,200 a year. “We were a major news story back then,” he says. “And that was essential to all of the victories that we had.”
Now, AIDS activists — drawn from that older generation, and from a new one — are working again to bring down the prices of HIV medication. This time, the drugmaker is Gilead Sciences, and the drug is Truvada. It’s the only FDA-approved version of PrEP, which stands for pre-exposure prophylaxis, currently available commercially in the U.S.
The list price? $1,780 a month, or $21,360 per year — more than 350 times the cost of generic versions of the drug available in most other countries.
“There are remarkable parallels to what’s happening with Gilead these days,” Staley says. “We are back to the Burroughs Wellcome days, where we have one company — we have a monopoly dominating the market and raking in money for what are actually government inventions. And we’re having massive access issues because of it.”
Still, the issue is playing out in a different era, Staley notes, and that’s requiring new tactics from advocates for patients.
“AIDS is an old story now,” he says. “That’s our new reality. So we accept it and we work around it.”
Today, though the HIV epidemic is quieter, it’s still deadly. People can live long lives with the virus, but there’s no cure, and it continues to spread. Gay and bisexual men, African Americans, Latinos and people living in the South are especially at risk.
Staley is now part of PrEP4All — an offshoot of ACT UP. The group was launched last summer, but is ramping up its activity now in light of the Trump administration’s plan to end the spread of HIV in America by 2030. That goal can only be reached if more people get on the PrEP regimen — currently only a fraction of the 1.1 million people at significant risk for getting HIV are taking the daily prevention pill.
To meet this new moment, Staley says, PrEP4All activists are using some of the same broad tactics as ACT UP, but also increasing their activity behind the scenes. They’re showing up in front page articles and editorials, at pharmaceutical shareholders meetings and publicly confronting officials in the Trump administration. They have a petition and a hashtag and a white paper — and have harnessed the tools of social media to help hold elected officials accountable.
“We have a congressional strategy, and we have what ACT UP never had — a legal strategy,” Staley says. “We’re working with deep-pocketed law firms, which is totally something that ACT UP never thought to do.”
He credits the young activists who are part of today’s movement for that new approach. “The sophistication by the millennial activists that I’m working with today has my head spinning,” Staley says. “They’ve got this historical template that says, ‘Anybody can do this. You just have to have the willpower and the self-confidence.’ They’re absolutely on fire — they already are making changes and they will continue to.”
Jake Powell, who works in New York City, is originally from Wyoming. Powell joined the PrEP4All movement after having to go off the drug for six months because it was too costly, even for someone with health insurance.
Courtesy of Brandon Cuicchi
hide caption
toggle caption
Courtesy of Brandon Cuicchi
The public “disruptions” PrEP4All has engaged in recently — along the lines of those ACT UP was known for — generally fall into two categories: shaming Gilead into voluntarily lowering the price of Truvada, and pressuring the government into challenging Gilead’s patent of the medication, so generic competition might force the price down.
“Our goal is to get Gilead Sciences to release the patent,” says Emily Sanderson, a co-founder of PrEP4All and one of the millennial activists Staley mentioned. “Gilead has the power to make PrEP available right now for everybody and they’re not doing it,” Sanderson says.
In mid-May at a congressional hearing focused on the price of Truvada, PrEP4All activist Dr. Aaron Lord made a personal appeal to Gilead CEO Daniel O’Day in front of lawmakers.
“Mr. O’Day, why not lower the price of Truvada to $15 a month, right here, today, at this hearing?” Lord asked. “We look to you today to ensure that every single person in this country can protect themselves from this plague.”
O’Day did not respond to that appeal. Instead, throughout the hearing, he explained the company’s rationale.
“The pricing set in the United States takes into account the innovation it brings, the cost of the health care of treating an HIV patient, [and] the ability to invest back in research and development,” O’Day said. He also said the company was working to “make sure our access programs are effective” so that price was not a barrier for patients.
From Gilead’s perspective, Truvada is under patent for a limited time and shareholders want to see profits. Gilead also argues the price isn’t the problem — lack of awareness, stigma and homophobia are the problems.
Gilead also points out that relatively few patients have to pay the list price. The company provides the drug at a discount to government programs; it just donated some 2.4 million bottles of Truvada a year to the Centers for Disease Control and Prevention to cover some uninsured patients; and it has a copay assistance program for people with high deductibles.
PrEP4All activists are generally dismissive of these efforts.
In a Manhattan demonstration this spring, members of ACT UP protest drug company lobbying of elected officials. The AIDS activists see Truvada’s high price as another example of profiteering by some makers of prescription drugs.
Courtesy of Brandon Cuicchi
hide caption
toggle caption
Courtesy of Brandon Cuicchi
“They’ll highlight their access programs. They’ll highlight the ways that some folks are covered. But there are so many gaps,” says activist Jake Powell, who takes PrEP. “And I personally fell through one of those gaps.” The gap occurred when Powell’s high-deductible insurance plan, which had accepted Gilead’s copay assistance for one year, stopped counting the payments towards the deductible the second year.
“I was off [PrEP] for about six months because I couldn’t afford it,” Powell says.
The activists are also focused on the government’s role in allowing the price of Truvada to stay high. “The CDC can come in and reduce the cost of PrEP and provide it at an affordable price,” Sanderson argues.
PrEP4All makes two points on this front. The first, detailed in a recent investigation by The Washington Post, is that the CDC has its own valid patents for PrEP that the agency could be enforcing (something Gilead disputes) and that taxpayer money was used in the studies underlying Gilead’s Truvada patent. Secondly, the activists argue, the government has the power under the Bayh-Doyle Act of 1980 to “march in” and break Gilead’s patent in the name of public health, so that competition from generics could bring the price down.
So far, neither the CDC nor Gilead have shown signs, at least publicly, of being moved by PrEP4All’s arguments. I ask Peter Staley if that lack of response from Gilead and the CDC is discouraging.
“The patent issue is very much bubbling at a boil right under the surface,” Staley says. “It’s not visible to the public, but it is a raging issue. And there are Democrats on both the House side and the Senate that want answers and are not going to let this go.”
He pauses, then adds: “We won’t let them let it go.”
Toronto Superfan To Sit Courtside For Raptor’s Historic Game
Nav Bhatia, a Sikh immigrant and superfan, has been to every Toronto Raptors home game since the franchise started in 1995. He’ll be courtside for the Raptor’s first NBA Finals appearance in history.
Warriors Travel To Canada As Raptors Host Game 1 Of NBA’s Finals
The NBA Finals get under way Thursday night, and there’s a familiar team playing for the title: The Golden State Warriors. But for the Toronto Raptors, it’s their first trip to the finals.
Child Struck By Foul Ball At Cubs-Astros Game, Player Breaks Down In Tears
A young child is carried from the stands after being injured by a foul ball off the bat of Chicago Cubs’ Albert Almora Jr. during the fourth inning of a baseball game against the Houston Astros Wednesday.
David J. Phillip/AP
hide caption
toggle caption
David J. Phillip/AP
A young child was struck by a foul ball off the bat of Cubs outfielder Albert Almora Jr. in a terrifying scene during the fourth inning of Wednesday’s nationally televised game in Houston.
Almora, who kept his eyes on the ball as it whizzed past the third base line, passed the existing safety netting and into the stands at Minute Maid Park, clasped his head in his hands and let out a cry as fans gasped. Grief-stricken, he then fell to his knees burying his face in his arms. Fellow teammate Jason Heyward and manager Joe Maddon attempted to console him as he cried.
Meanwhile, the Astros infield also dropped to their knees as a man, who seemed to be with the girl, scooped her up and rushed the child up the stadium stairs.
Here is Albert Almora’s reaction as his foul ball struck a very young fan. A really horrific moment. Kids fall in love with the game of baseball after going to the ballpark and experiencing a Major League Baseball game. This shouldn’t happen. PRAYERS. ?? pic.twitter.com/yOGfrqpmMF
— Cubs Live (@Cubs_Live) May 30, 2019
Almora struggled to play through the remainder of the inning. When it was over, he walked into the stands where he spoke with a security guard. The conversation ended in an embrace with Almora becoming overcome with emotion.
After Albert Almora Jr. struck a young fan with a foul ball, in between innings he went immediately over to that section to ask about the situation. You can see he is overwhelmed with emotion as him and the security guard have a moment. This is just a terrible & sad situation. pic.twitter.com/Yh3wWmDjhx
— Cubs Live (@Cubs_Live) May 30, 2019
“All we heard was screaming,” said David LeVasseur told the Houston Chronicle. “We saw this dad pick up a child and run up the stairs. He took off running.”
LeVasseur said the ball eventually landed at his feet.
“I (came) upstairs and see the first-aid guys up there and the dad is holding the girl. She (was) alert, she’s conscious, she’s fine. I was just going to give somebody in the family the ball. They kind of, naturally, shook it off. I asked the first-aid guy if she was OK and he said he didn’t know.”
In a statement the Astros confirmed the girl was taken to the hospital but offered no details on her condition. “We are not able to disclose any further details at this time. The Astros send our thoughts and prayers to the entire family,” the team said.
The Astros released the following statement. Our thoughts are with the entire family. pic.twitter.com/f1VGVP1kiu
— Houston Astros (@astros) May 30, 2019
Speaking with reporters following the game, Almora said, “As soon as I hit it, the first person I locked eyes on was her.” He said the rest of the at-bat “was kind of a blur.”
“I had to try to keep my composure during that at-bat, but when that half-inning was over I just couldn’t hold it anymore,” he added.
In 2017 New York Yankee Todd Frazier hit a foul ball that struck a young girl in the stands. The incident renewed the debate over more extensive protection for fans in major league ballparks, eventually leading all 30 teams to implement extended safety nets in 2018.
